| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the MS Clinic (Drs. Roed, Sellebjerg, and Frederiksen), Department of Neurology, and Department of Clinical Neurophysiology (Dr. Lauritzen), University of Copenhagen, Glostrup Hospital, Glostrup, Danish Research Centre for Magnetic Resonance (Dr. Langkilde), University of Copenhagen, Hvidovre Hospital, Hvidovre, and Medical Department (P. Bang) and Biostatistical Unit (A. Mørup), Statens Serum Institut, Copenhagen, Denmark.
Address correspondence and reprint requests to Dr. H.G. Roed, Department of Neurology, Glostrup Hospital, University of Copenhagen, DK-2600 Glostrup, Denmark; e-mail: roeden{at}dadlnet.dk
Objective: To investigate if IV immunoglobulin (IVIG) treatment in the acute phase of optic neuritis (ON) could improve visual outcome and reduce MRI disease activity 6 months after onset of ON.
Methods: Sixty-eight patients with ON were randomized within 4 weeks from onset of symptoms. Thirty-four patients were randomized to IVIG 0.4 g/kg body wt, and 34 patients were randomized to placebo. Infusions were given at days 0, 1, 2, 30, and 60. Contrast sensitivity, visual acuity, and color vision were measured at baseline and after 1 week, 1 month, and 6 months. Pattern reversal visual evoked potential studies and gadolinium-enhanced MRI were performed at baseline and after 1 and 6 months. Clinical relapses during follow-up were recorded.
Results: There was no difference in the primary outcome, contrast sensitivity after 6 months, between patients randomized to treatment with IVIG or placebo. In addition, there was no significant difference in the secondary outcome measures, improvement in the visual function measures and MRI, at any time during follow-up. At baseline, a significantly higher number of patients in the IVIG group had one or more enhancing lesions on MRI and IVIG-treated patients had a significantly higher number of enhancing lesions on MRI than patients treated with placebo. No difference was found in number of patients with one or more enhancing lesions or number of enhancing lesions in subsequent scans between treatment groups. Number of relapses was equal in the two treatment groups during follow-up.
Conclusions: There was no effect of IV immunoglobulin (IVIG) on long-term visual function following acute optic neuritis, nor was there an effect of IVIG treatment in reducing latency on visual evoked potentials and thus preserving function of axons of the optic nerve.
Related Article
Neurology 2005 64: 772-773.
This article has been cited by other articles:
|
|
 |
|
  B. J. OSBORNE and N. J. VOLPE Optic neuritis and risk of MS: Differential diagnosis and management Cleveland Clinic Journal of Medicine, March 1, 2009; 76(3): 181 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Niklas, H Sebraoui, E Hess, A Wagner, and F Then Bergh Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency Multiple Sclerosis, January 1, 2009; 15(1): 68 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]
|
|
|
|
 |
|
 L. J. Balcer Clinical practice. Optic neuritis. N. Engl. J. Med., March 23, 2006; 354(12): 1273 - 1280. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
